Ide-Cel & Enhertu Sponsors Keep Fingers Crossed For EMA Fast-Track

 
• By Neena Brizmohun

Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.

Tablet_Multiple_Myeloma
Ide-cel is BMS and bluebird bio's BMCA-targeting therapy for multiple myeloma • Source: Shutterstock

More from Product Reviews

More from Pink Sheet